US OptionsDetailed Quotes
NVAX240816C13500
- 0.05
- -0.03-37.50%
15min DelayClose Aug 14 16:00 ET
0.14High0.03Low
0.12Open0.08Pre Close278 Volume592 Open Interest13.50Strike Price1.84KTurnover109.35%IV11.16%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1096Delta0.1917Gamma243.80Leverage Ratio-0.0401Theta0.0001Rho26.71Eff Leverage0.0017Vega
Novavax Stock Discussion
yesterday action
- pre market and early market down 18 percent after result release
- within the same day , recovered all the losses and gain 10 percents
my intepretation
1) trader deliberate sell down , flushing out weak holders and triggering stop loss
2) big fish like sanofi coming in to collect shares at low
Going ahead, with the results out of the way and mid term finance sorted
i only see upside at this price point ( sanofi brought 10 , SK at 13 ) with near term mult...
★★ Key Points Summary
Sanofi Partnership Progress:
- Partnership Terms: Novavax's collaboration with Sanofi involves an upfront payment and equity investment totaling $570 million, with potential milestone payments reaching $700 million. The deal includes long-term royalties from COVID-19 vaccine and Matrix-M adjuvant sales.
- Commercialization Transition: Sanofi will take over commercialization in 2025, allowing Novavax to shift focus to research...
imagine the pain
As reported by Forbes. The Novavax updated vaccine is much superior to the the moderna and Pfizer. It creates 48x antibodies while Moderna and Pfizer created 7x or 8x only.
Why? The answer is imprinting. Once you get a shot of Wuhan mRNA vaccine the body remembers it and will always produce antibodies agai...
dipping
down
againnnnn
"We’re all in on AI. We want to become the first biopharma company powered by AI at scale" -
"We invest in AI that makes a difference for our people, patients, and partners" - #sanofi
Novavax
- 2021 Gets $1.6 billion government grant to develop its COVID shot
- Stock soars over $280
- 2024 - Sanofi is taking a 4.9% equity position in Novavax with 1.2 billion dollar deal with $500 Million up front.
- Malaria WHO Approved & rolled...
Vivek Shinde, the Vice President of Clinical Development at Novavax, recently discussed the company's innovative use of machine learning (ML) tools to improve the process of determining vaccine doses. Traditionally, this process has been quite crude and simplistic. However, by employing ML, Novavax was able to vary different components of a multi-component vaccine and use ML to understand the entire surface of response in a three-dimensional space.
In particular...
No comment yet